NASDAQ: LQDA · Life Sciences · 16 alerts · CIK 1819576
Share price
$56.37Close, Nov 16
Market cap
$5.08B
Shares outstanding
90.11MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Liquidia Corp filings on SEC EDGAR ↗
Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.
Term
Q3 2026
“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”
Dr. Roger Jeffs, Liquidia’s Chief Executive Officer
Liquidia Corp is a non-accelerated filer focused on the commercialization of YUTREPIA and the development of L606 for pulmonary hypertension. As of October 28, 2026, the company reported 90,106,442 shares of common stock outstanding and is navigating ongoing legal settlements and regulatory filings with the FDA.
Dana Boyle, CAO, sold 1,581 shares of Liquidia Corp at $43.19 a share, worth $68.3K in total on Oct 26, 2026. Shares held after the trade: 164,028 (-1.0%).
Liquidia Chief Business Officer Jason Adair Sells $29.7K of Stock
Jason Adair, Chief Business Officer, sold 688 shares of Liquidia Corp at $43.19 a share, worth $29.7K in total on Oct 26, 2026. Shares held after the trade: 177,269 (-0.4%).
Liquidia Corporation entered into a global settlement agreement with United Therapeutics to resolve all ongoing patent infringement, trade secret, and antitrust litigation. Liquidia will make aggregate payments of $320.4 million to UTC ($175M net initial payment plus $145.4M in 2027 installments) while agreeing to remove the PH-ILD indication from its YUTREPIA label to maintain the product's availability for PAH patients.
Counterparty
United Therapeutics Corporation
“Today’s agreement fully resolves years of litigation and provides certainty to PAH patients that they can continue to access YUTREPIA, whose differentiated attributes have enabled its rapid adoption by physicians and patients since launch.”
Liquidia General Counsel Russell Schundler Sells $390K of Stock
Russell Schundler, General Counsel, sold 13,692 shares of Liquidia Corp at $28.48 a share, worth $390K in total on Oct 12, 2026. Shares held after the trade: 602,841 (-2.2%).
Rajeev Saggar, CMO, sold 9,218 shares of Liquidia Corp at $28.48 a share, worth $263K in total on Oct 12, 2026. Shares held after the trade: 126,368 (-6.8%).
Liquidia Chief Commercial Officer Scott Moomaw Sells $252K of Stock
Scott Moomaw, Chief Commercial Officer, sold 8,863 shares of Liquidia Corp at $28.48 a share, worth $252K in total on Oct 12, 2026. Shares held after the trade: 181,487 (-4.7%).
Liquidia Chief Human Resource Officer Sarah Krepp Sells $149K of Stock
Sarah Krepp, Chief Human Resource Officer, sold 5,245 shares of Liquidia Corp at $28.48 a share, worth $149K in total on Oct 12, 2026. Shares held after the trade: 115,241 (-4.4%).
Liquidia Chief Development Officer Sanjeev Khindri Sells $31.4K of Stock
Sanjeev Khindri, Chief Development Officer, sold 1,101 shares of Liquidia Corp at $28.48 a share, worth $31.4K in total on Oct 12, 2026. Shares held after the trade: 64,846 (-1.7%).
Liquidia CFO and COO Michael Kaseta Sells $539K of Stock
Michael Kaseta, CFO and COO, sold 18,938 shares of Liquidia Corp at $28.48 a share, worth $539K in total on Oct 12, 2026. Shares held after the trade: 340,148 (-5.3%).
Roger Jeffs, CEO, sold 32,744 shares of Liquidia Corp at $28.48 a share, worth $933K in total on Oct 12, 2026. Shares held after the trade: 1,125,848 (-2.8%).
Dana Boyle, CAO, sold 5,892 shares of Liquidia Corp at $28.48 a share, worth $168K in total on Oct 12, 2026. Shares held after the trade: 165,609 (-3.4%).
Liquidia Chief Business Officer Jason Adair Sells $208K of Stock
Jason Adair, Chief Business Officer, sold 7,301 shares of Liquidia Corp at $28.48 a share, worth $208K in total on Oct 12, 2026. Shares held after the trade: 177,957 (-3.9%).
Liquidia Insider Stephen M. Bloch Sells $6.39M of Stock
Stephen M. Bloch sold 235,477 shares of Liquidia Corp at $27.13 a share, worth $6.39M in total on Oct 5, 2026. Shares held after the trade: 0 (-100.0%).
The U.S. District Court for the District of Delaware ruled that Liquidia's lead product, YUTREPIA, infringed on two valid claims of United Therapeutics' '327 patent. Liquidia intends to appeal the decision and may seek to remove the PH-ILD indication from its label to mitigate potential injunctive relief that could restrict the product's market availability.